Literature DB >> 7692082

A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

T Muster1, F Steindl, M Purtscher, A Trkola, A Klima, G Himmler, F Rüker, H Katinger.   

Abstract

Vaccination against human immunodeficiency virus type 1 (HIV-1) requires an immunogen which will elicit a protective immunity against viruses that show a high degree of genetic polymorphism. Therefore, the identification of neutralizing epitopes which are shared by many strains would be useful. In previous studies, we established a human monoclonal antibody (2F5) that neutralizes a variety of laboratory strains and clinical isolates of HIV-1. In the present report, we define the amino acid sequence Glu-Leu-Asp-Lys-Trp-Ala (ELDKWA) on the ectodomain of gp41 as the epitope recognized by this antibody. The sequence was found to be conserved in 72% of otherwise highly variable HIV-1 isolates. Escape mutants were not detected in cells infected with HIV-1 isolates MN and RF in the presence of antibody 2F5. Since sequence variability of neutralizing epitopes is considered to be a major obstacle to HIV-1 vaccine development, the conserved B-cell epitope described here is a promising candidate for inclusion in a vaccine against AIDS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692082      PMCID: PMC238102     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Authors:  W E Robinson; M K Gorny; J Y Xu; W M Mitchell; S Zolla-Pazner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  In vitro generation of an HTLV-III variant by neutralizing antibody.

Authors:  M Robert-Guroff; M S Reitz; W G Robey; R C Gallo
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

4.  Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.

Authors:  M S Reitz; C Wilson; C Naugle; R C Gallo; M Robert-Guroff
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

5.  Mechanisms associated with the generation of biologically active human immunodeficiency virus type 1 particles from defective proviruses.

Authors:  M Inoue; J A Hoxie; M V Reddy; A Srinivasan; E P Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

6.  Tumor promoter, TPA, enhances replication of HTLV-III/LAV.

Authors:  S Harada; Y Koyanagi; H Nakashima; N Kobayashi; N Yamamoto
Journal:  Virology       Date:  1986-10-30       Impact factor: 3.616

7.  A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS.

Authors:  D Zagury; J Bernard; R Cheynier; I Desportes; R Leonard; M Fouchard; B Reveil; D Ittele; Z Lurhuma; K Mbayo
Journal:  Nature       Date:  1988-04-21       Impact factor: 49.962

8.  Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Authors:  T J Palker; M E Clark; A J Langlois; T J Matthews; K J Weinhold; R R Randall; D P Bolognesi; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

9.  Type-restricted neutralization of molecular clones of human immunodeficiency virus.

Authors:  D J Looney; A G Fisher; S D Putney; J R Rusche; R R Redfield; D S Burke; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1988-07-15       Impact factor: 47.728

10.  Induction of anti-HIV neutralizing antibodies by synthetic peptides.

Authors:  T C Chanh; G R Dreesman; P Kanda; G P Linette; J T Sparrow; D D Ho; R C Kennedy
Journal:  EMBO J       Date:  1986-11       Impact factor: 11.598

View more
  479 in total

1.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Authors:  R W Sanders; L Schiffner; A Master; F Kajumo; Y Guo; T Dragic; J P Moore; J M Binley
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.

Authors:  A L Edinger; M Ahuja; T Sung; K C Baxter; B Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins.

Authors:  Christoph Grundner; Tajib Mirzabekov; Joseph Sodroski; Richard Wyatt
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Authors:  C E Parker; L J Deterding; C Hager-Braun; J M Binley; N Schülke; H Katinger; J P Moore; K B Tomer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 6.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

8.  Analysis of genetic variability within the immunodominant epitopes of envelope gp41 from human immunodeficiency virus type 1 (HIV-1) group M and its impact on HIV-1 antibody detection.

Authors:  J Dorn; S Masciotra; C Yang; R Downing; B Biryahwaho; T D Mastro; J Nkengasong; D Pieniazek; M A Rayfield; D J Hu; R B Lal
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

9.  Antigenic properties of the HIV envelope on virions in solution.

Authors:  Krishanu Ray; Meron Mengistu; Lei Yu; George K Lewis; Joseph R Lakowicz; Anthony L DeVico
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

10.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.